GlaxoSmithKline (GSK) is aiming to manufacture one billion doses of its pandemic vaccine adjuvant system, in 2021, to support the development of multiple adjuvanted COVID-19 vaccine candidates.
As demonstrated in the last flu pandemic, GSK’s pandemic adjuvant can reduce the amount of vaccine protein required per dose, which allows more vaccine doses to be produced, contributing to protecting more people.
Additionally, an adjuvant can enhance the immune response and has been shown to create a stronger and longer-lasting immunity against infections.
GSK has prioritised its efforts towards making its pandemic adjuvant technology available to partners developing promising COVID-19 vaccine candidates that are suitable for use with an adjuvant.
To date, the company has formed several collaborations, including with scientific partners in North America, Europe and China, to develop vaccines. Discussions with potential partners on further collaborations are ongoing.
Confirmation of the enhanced manufacturing capacity follows completion of a review conducted across the company’s global supply network. GSK will manufacture, fill and finish adjuvant for use in COVID-19 vaccines at sites in the UK, US, Canada and Europe.
“We believe that more than one vaccine will be needed to address this global pandemic and we are working with partners around the world to do so. We believe that our innovative pandemic adjuvant technology has the potential to help improve the efficacy and scale up of multiple COVID-19 vaccines,” said Roger Connor, President of GSK Global Vaccines.
“With this significant expansion in our manufacturing capacity, we can help deliver up to 1 billion doses of adjuvanted vaccines through 2021, helping protect many more people and support the global effort to fight COVID-19.”
Given the unprecedented need to develop COVID-19 vaccines, GSK has started manufacture of the adjuvant at risk. The company is in discussions with Governments and global institutions about funding for production and supply of the adjuvant.